Amylyx Pharmaceuticals
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Amylyx Pharmaceuticals (AMLX) | 3.35B | -18.20 | 4.44 | 0.00% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 5.8% above Morningstar's fair value estimate.
Fair value
Amylyx Pharmaceuticals Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 24% premium over our quantitative fair value estimate of $24.50 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.
The company's lack of profitability decreases our estimated fair value. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of -3.9%, which ranks in the bottom 20% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.
The firm's liquidity is an additional cause for concern. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, for example, lies in the top 30% globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. This characteristic further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.
Amylyx Pharmaceuticals discussion 0 comments